Antiepileptic drugs and cognitive disorders

The Neuropsychiatry of Epilepsy, Second Edition

Volumn , Issue , 2011, Pages 153-164

  Aldenkamp, Albert P ^a,b,c  

^a EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Division Neurosciences of the Research School MHeNS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919395489     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511977145.015     Document Type: Chapter

References (86)

1. Aarts JH, Binnie CD, Smit AM, Wilkins AJ. Selective cognitive impairment during focal and generalized epileptiform EEG activity. Brain 1984;107:293-308.
2. Äikiä M, Kälviäinen R, Sivenius J, et al. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 1992;11:199-203.
3. Aldenkamp AP. Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults. Neurology 2000;54:270-2.
4. Aldenkamp AP. Cognitive and behavioural assessment in clinical trials: when should they be done? Epilepsy Res 2001;45:155-9.
5. Aldenkamp AP. Antiepileptic drug treatment and epileptic seizures: effects on cognitive function. In: Trimble M, Schmitz B, eds. The Neuropsychiatry of Epilepsy. New York: Cambridge University Press, 2002: 256-67.
6. Aldenkamp AP, Dodson WE, eds. Epilepsy and education; cognitive factors in learning behavior. Epilepsia 1990;31(Suppl 4):S9-S20.
7. Aldenkamp AP, Alpherts WCJ, Blennow G, et al. Withdrawal of antiepileptic medication - effects on cognitive function in children: The Multicentre Holmfrid Study. Neurology 1993;43:41-50.
8. Aldenkamp AP, Dreifuss FE, Renier WO, Suumeijer PBM. Epilepsy in Children and Adolescents. Boca Raton, Fla: CRC Press, 1995.
9. Aldenkamp AP, Mulder OG, Overweg J. Cognitive effects of lamotrigine as first line add-on in patients with localized related (partial) epilepsy. J Epilepsy 1997;10:117-121.
10. Aldenkamp AP, Baker G, Mulder OG, et al. A multicentre randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41:1167-78.
11. Aldenkamp AP, Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav 2001;2:85-91.
12. Aldenkamp AP, Arends J, Overweg-Plandsoen TC, et al. Acute cognitive effects of nonconvulsive difficult- to-detect epileptic seizures and epileptiform electroencephalographic discharges. J Child Neurol 2001;16:119-23.
13. Aldenkamp AP, Arends J, Bootsma HP, et al. Randomized, double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 2002;43: 19-26.
14. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003;44 (Suppl 4):21-9.
15. Aldenkamp AP, Alpherts WCJ. The effect of the new antiepileptic drug rufinamide on cognitive function. Epilepsia 2006;47(7):1153-9. PubMed PMID: 16886978.
16. American Academy of Pediatrics. Behavioral and cognitive effects of anticonvulsant therapy. Committee on Drugs. Pediatrics 1985;76:644-7.
17. Banks GK, Beran RG. Neuropsychological assessment in lamotrigine treated epileptic patients. Clin Exp Neurol 1991;28:230-7.
18. Binnie CD, van Emde BW, Kasteleijn-Nolste-Trenite DG, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-54.
19. Bootsma HP, Coolen F, Aldenkamp AP, et al. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 2004;5(3):380-7.
20. Burton LA, Harden C. Effect of topiramate on attention. Epilepsy Res 1997;27:29-32.
21. Calandre EP, Dominguez-Granados R, Gomez-Rubio M, et al. Cognitive effects of long-term treatment with phenobarbital and valproic acid in school children. Acta Neur Scand 1990;81:504-6.
22. Chadwick DW, Marson T, Kadir Z. Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. Epilepsia 1996;37(Suppl 6):S17-22.
23. Cohen AF, Ashby L, Crowley D, et al. Lamotrigine (BW430C), a potential anticonvulsant: effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 1985;20:619-29.
24. Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 1994;35:381-90.
25. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993;44:529-33.
26. Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin. Neurology 1977;27:1023-28.
27. Dodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997;48:1025-31.
28. Dodson WE, Pellock JM. Pediatric Epilepsy: Diagnosis and treatment. New York: Demos Publications, 1993.
29. Dodson WE, Trimble MR. Epilepsy and Quality of Life. New York: Raven Press, 1994.
30. Donati F, Gobbi G, Campistol J, et al. Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. Neurology 2006;67 (4):679-82.
31. Donati F, Gobbi G, Campistol J, et al.; on behalf of The Oxcarbazepine Cognitive Study Group. The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures. Seizure 2007;16(8):670-9.
32. Earl N, McKee JR, Sunder TR, et al. Lamotrigine adjunctive therapy in patients with refractory epilepsy and mental retardation [Abstract]. Epilepsia 2000;41 (Suppl 1):72.
33. Ettinger AB, Weisbrot DM, Saracco J, et al. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39:874-7.
34. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo- controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
35. Forsythe I, Butler R, Berg I, et al. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol 1991;33:524-34.
36. Fritz N, Glogau S, Hoffmann J, et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005;6(3):373-81.
37. Gallassi R, Morreale A, Di Sarro R, et al. Cognitive effects of antiepileptic drug discontinuation. Epilepsia 1992;33 (Suppl 6):S41-4.
38. Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health- related quality of life as an outcome measure. Seizure 2000;9:375-9.
39. Hamilton MJ, Cohen AF, Yuen AW, et al. Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia 1993;34:166-73.
40. Ideström CM, Schalling D, Carlquist U, Sjoqvist F. Acute effects of diphenylhydantoin in relation to plasma levels: behavioral and psychological studies. Psychol Med 1972;2:111-20.
41. Jette NJ, Marson AG, Hutton JL. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002;(3):CD001417.
42. Kälviäinen R, Äikiä M, Mervaala E, et al. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res 1996;25:291-7.
43. Kellet MW, Smith DF, Stockton PA, Chadwick DW. Topiramate in clinical practice: first year’s postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999;66:759-63.
44. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53(5 Suppl 2):53-67.
45. Laaksonen R, Kaimola K, Grahn-Teräväinen E, Waltimo O. A controlled clinical trial of the effects of carbamazepine and oxcarbazepine on memory and attention. 16th International Epilepsy Congress, Hamburg, 1985 (abstract).
46. Leach MJ, Lees G, Riddall DR. Lamotrigine: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic Drugs, 4th edn. New York: Raven Press, 1995:861-9.
47. Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997;62:372-6.
48. Lhatoo SD, Wong ICK, Sander JW. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000;41:338-41.
49. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36(S2):2-12.
50. MacLeod CM, Dekaban AS, Hunt E. Memory impairment in epileptic patients: selective effects of phenobarbital concentration. Science 1978;202:1102-4.
51. Marciani MG, Spanedda F, Bassetti MA, et al. Effect of lamotrigine on EEG paroxysmal abnormalities and background activity: a computerized analysis. Br J Clin Pharmacol 1996;42:621-7.
52. Marciani MG, Stanzione P, Mattia D, et al. Lamotrigine add-on therapy in focal epilepsy: electroencephalographic and neuropsychological evaluation. Clin Neuropharmacol 1998;21:41-7.
53. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38:859-80.
54. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. Gabapentin for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2000;(2):CD001415.
55. Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 2001;46:259-70.
56. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52:321-7.
57. McKee PJ, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994;37:27-32.
58. Meador KJ. Assessing cognitive effects of a new AED without the bias of practice effects [Abstract]. Epilepsia 1997;38(Suppl 3):60.
59. Meador KJM, Loring DW, Huh K, et al. Comparative cognitive effects of anticonvulsants. Neurology 1990;40:391-4.
60. Meador KJM, Loring DW, Allen ME, et al. Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology 1991;41:1537-40.
61. Meador KJM, Loring DW, Abney OL, et al. Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia 1993;34(1):153-7.
62. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999;40:1279-85.
63. Meador KJ, Loring DW, Ray PG, et al. Differential effects of carbamazepine and lamotrigine [Abstract]. Neurology 2000;54(Suppl 3):A84.
64. Mervaala E, Koivista K, Hanninen T, et al. Electrophysiological and neuropsychological profiles of lamotrigine in young and age-associated memory impairment (AAMI) subjects [Abstract]. Neurology 1995;45(Suppl 4):A259.
65. Mortimore C, Trimble M, Emmers E. Effects of gabapentin on cognition and quality of life in patients with epilepsy. Seizure 1998;7:359-6.
66. Neyens LGJ, Alpherts WCJ, Aldenkamp AP. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:411-9.
67. Petroff OAC, Rothman DL, Behar KL, et al. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996;39: 95-9.
68. Prevey ML, Delaney RC, Cramer JA, et al. Effect of valproate on cognitive function: comparison with carbamazepine. The Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Arch Neurol 1996;53(10):1008-16.
69. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Topiramate YE Study Group. Neurology 1996;46:1678-83.
70. Sabers A, Moller A, Dam M, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand 1995;92:19-27.
71. Schwarz JR, Grigat G. Phenytoin and carbamazepine: potential- and frequency-dependent block of NA currents in mammalian myelinated nerve fibers. Epilepsia 1989;30:286-94.
72. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-22.
73. Smith WL, Lowrey JB. Effects of diphenylhydantoin on mental abilities in the elderly. J Am Geriatr Soc 1975;23:207-11.
74. Stefan H, Krämer G, Mamoli B, eds. Challenge Epilepsy - New Antiepileptic Drugs. Berlin: Blackwell Science, 1998.
75. Sveinbjornsdottir S, Sander JW, Patsalos PN, et al. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994;3:29-35.
76. Tatum WO, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001;42:1134-40.
77. Thompson PJ, Trimble MR. Sodium valproate in cognitive functioning in normal volunteers. Br J Clin Pharmacol 1981;12:819-24.
78. Thompson PJ, Huppert F, Trimble MR. Anticonvulsant drugs, cognitive function and memory. Acta Neurol Scand 1980;S80:75-80.
79. Thompson PJ, Huppert FA, Trimble MR. Phenytoin and cognitive functions: effects on normal volunteers and implications for epilepsy. Br J Clin Psychol 1981;20: 155-62.
80. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000;69:636-41.
81. Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987;28(Suppl 3):37-45.
82. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989;25:213-20.
83. Vermeulen J, Aldenkamp AP. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res 1995;22:65-95.
84. Vining EP, Mellitis ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987;80(2):165-74.
85. White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997;38(Suppl 1):S9-S17.
86. Wong IC. New antiepileptic drugs: study suggests that under a quarter of patients will still be taking the new drugs after six years. BMJ 1997;314:603-4.